Abstract
Patients undergoing hematopoietic stem cell transplantation (HSCT) and adoptive cell therapies (ACT) are at an increased risk of venous thromboembolism (VTE) [1,2]. A concurrently elevated risk of bleeding in the setting of thrombocytopenia, graft versus host disease (in recipients of allogeneic HSCT) and coagulopathy complicates therapeutic anticoagulation (TAC) in this patient population [3,4]. TAC, when administered to HSCT and ACT patients in the peri-transplant setting at our center, is achieved with the low-molecular weight heparin (LMWH) enoxaparin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
